Two recently published articles from Siegers and colleagues detail both a novel human gamma delta T cell (GDTc) expansion protocol and a bioluminescent xenograft model of Ph + leukemia, in which GDTc adoptive therapy was tested. Additionally, B-cell chronic lymphocytic leukemia-derived cells were newly identified as targets of preferentially expanded Vdelta1 GDTc.
Anti-Leukemia Activity of Human Gamma Delta T Cells
Once an obscure cell type receiving little attention, gamma delta T cells (GDTc) are now coming into their own, as new studies are published at an ever-increasing rate. GDTc are immunosurveillance cells, comprising 2-5% of circulating lymphocytes in humans. Ensslin initially reported on MHC-unrestricted GDTc lysis of tumor cell lines. 1 We have since learned that GDTc recognition and tumor lysis can be mediated by T cell antigen receptor (TCR), the natural killer receptor NKG2D, as well as fas-fasL interactions, depending on GDTc subset and target.
Promising reports from recent clinical trials support the use of GDTc as immunotherapeutic agents; either via adoptive transfer 2 or in vivo stimulation with compounds such as IPH1101 3 or the aminobisphosphonate zoledronate. 4 While the autologous setting is preferable for adoptive transfer, a report of allotransplantation without the incidence of graft-vs.-host disease suggests that this is also clinically feasible. 5 The study of GDTc has recently been rendered more accessible with the advent of magnetic cell separation allowing positive or negative selection of GDTc from blood or tissues. With the ultimate goal of clinical translation, we used this technology to develop a novel protocol to isolate human GDTc from peripheral blood and expand pure populations to clinically relevant numbers, without the use of irradiated feeder cells. Additionally, we identified new GDTc subset-specific targets and presented results from preclinical immunotherapy experiments. 6, 7 Our GDTc expansion protocol expands both Vgamma9Vdelta2 GDTc (Vd2) and also the lesser-prevalent Vdelta1 GDTc (Vd1) subset from human blood. 6 A correlation between duration of initial GDTc exposure to Concanavalin A (ConA) and expansion of Vd1 was evident (Fig. 1A ). Bartkowiak and colleagues reported an expanded population of Vd1 in the blood of B-CLL patients. 8 Thus, using mixed Vd1/Vd2 cultures, the CD107 mobilization assay 9 was employed to simultaneously test activation of GDTc subsets against Philadelphia chromosome positive (Ph + ) or B-cell chronic lymphocytic leukemia (B-CLL)-derived cells. Indeed, this approach could be applied to any target of interest. While Ph + EM2 cells only activated Vd2, both Vd1 and Vd2 were activated by B-CLL-derived MEC1 and TMD2 (Fig. 1B) , thus obviating the need to separate subsets for possible future autologous cellular therapy of B-CLL. An interesting line of study made uniquely possible by generation of mixed cultures is the influence exerted by one GDTc subset on the other; for example, one could explore whether Vd2 activation suppresses Vd1.
Finally, some indications as to which receptors play a role in GDTc cytotoxicity against their targets were obtained by correlating surface marker expression with differential cytotoxicity exhibited by a panel of Vd1 and Vd2 clones. TCR, CD56 and CD95 expression correlated with Vd1 cytotoxicity, while both TCR and NKG2D were implicated in that of Vd2. Although perhaps unconventional, using this panel of clones proved advantageous over the antibody blocking experiments typically employed to elucidate mechanism. Initial attempts at blocking failed when FcR-mediated apoptosis occurred in B-CLL-derived cells, incited even by isotype control antibodies. Further verification of results via blocking will require the generation of Fab fragments.
Comparing antigen expression on target cell lines in parallel provided additional information. The absence of HLA class I on the surface of EM2eGFPluc cells pointed to the "missing self" mechanism by which Daudi lymphoma cells are killed by Vd2.
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TRAILR1 expression was elevated on B-CLL derived cell lines but not EM2eGFPluc, suggesting involvement of this surface antigen in Vd1 cytotoxicity. Much work lies ahead to further elucidate these cytotoxic mechanisms.
Our other study focused on expanding Vd2 GDTc for use in a novel bioluminescent xenograft model of Ph + leukemia. /SzJ mice (Fig. 1C) , closely emulating human pathogenesis, with leukemia engraftment restricted largely to the bone marrow, as monitored in live mice via IVIS 1 technology (Fig. 1D , In Vivo Imaging System, Xenogen). Expanded GDTc were cytotoxic to Ph + leukemia cell lines in vitro and thus administered in vivo with the goal of eradicating leukemia. Intraperitoneal injection elicited enhanced GDTc engraftment compared with IV. Although different dosages were attempted, no apparent survival advantage was achieved. However, reduced leukemia burden was evidenced in some treated mice. In the absence of an intact immune system, tumor burden quickly progressed to a blast crisis state, overwhelming GDTc. Potential improvements for future studies include: lowering the initial leukemia dose; increasing the number and frequency of GDTc administration; raising IL-2 doses; or injecting GDTc in the context of whole peripheral blood mononuclear cells.
We have reported on a new protocol that can be manipulated to preferentially expand Vd1 or Vd2 subsets from human blood. Vd1 are cytotoxic to B-CLLderived cells, suggesting that Vd1 may represent a novel cellular therapy for B-CLL. Vd2 targeting of Ph + leukemia cells was demonstrated and immunotherapy experiments performed in a novel bioluminescent xenograft model of Ph + leukemia. Despite the disappointing survival outcome of preclinical therapy experiments, decreased leukemia burden in some treated mice supports this line of investigation. Especially promising was detection of GDTc in the bone marrow of treated mice at the experimental endpoint, indicating GDTc localization to tumors, though whether migration was truly targeted was not addressed. The report of both a new GDTc expansion protocol and bioluminescent Ph + leukemia model provides further tools with which we can contribute to the growing body of evidence supporting the development of GDTc as immunotherapeutic agents targeting leukemia. 
